Analysts are on the Bearish side about Envision Healthcare Corporation (NYSE:EVHC) this week.

June 16, 2018 - By Michael Collier

Envision Healthcare Corporation (NYSE:EVHC) Ratings Coverage

Among 13 analysts covering Envision Healthcare (NYSE:EVHC), 3 have Buy rating, 0 Sell and 10 Hold. Therefore 23% are positive. Envision Healthcare had 28 analyst reports since December 20, 2017 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Wednesday, February 21 with “Hold”. The firm has “Hold” rating given on Wednesday, January 24 by Mizuho. Robert W. Baird maintained it with “Buy” rating and $5000 target in Wednesday, April 11 report. Jefferies maintained Envision Healthcare Corporation (NYSE:EVHC) on Wednesday, February 7 with “Buy” rating. The stock has “Hold” rating by Canaccord Genuity on Wednesday, June 13. The firm has “Buy” rating given on Tuesday, May 8 by Canaccord Genuity. The company was maintained on Thursday, March 1 by RBC Capital Markets. The rating was downgraded by RBC Capital Markets to “Hold” on Tuesday, June 12. As per Wednesday, February 28, the company rating was maintained by Stephens. Cantor Fitzgerald maintained Envision Healthcare Corporation (NYSE:EVHC) on Tuesday, April 10 with “Hold” rating. Below is a list of Envision Healthcare Corporation (NYSE:EVHC) latest ratings and price target changes.

13/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Hold Old Target: $48 New Target: $46 Downgrade
12/06/2018 Broker: Raymond James Old Rating: Strong Buy New Rating: Market Perform Old Target: $51 Downgrade
12/06/2018 Broker: SunTrust Rating: Hold Downgrade
12/06/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
11/06/2018 Broker: Robert W. Baird Rating: Hold Downgrade
11/06/2018 Broker: William Blair Rating: Hold Downgrade
08/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $48.0000 Maintain
07/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $40.0000 Maintain
11/04/2018 Broker: Robert W. Baird Rating: Buy New Target: $50.0000 Maintain
10/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $40.0000 Maintain

The stock decreased 0.25% or $0.11 during the last trading session, reaching $44.67. About 7.12M shares traded or 80.10% up from the average. Envision Healthcare Corporation (NYSE:EVHC) has declined 22.24% since June 16, 2017 and is downtrending. It has underperformed by 34.81% the S&P500.

Envision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company has market cap of $5.34 billion. The firm operates through three reportable divisions: Physician Services, Medical Transportation, and Ambulatory Services. It has a 42.62 P/E ratio. The Company’s physician-led services encompass providers at approximately 1,500 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services.

More notable recent Envision Healthcare Corporation (NYSE:EVHC) news were published by: Streetinsider.com which released: “Envision Healthcare (EVHC) Near Deal to Be Acquired by KKR” on June 11, 2018, also Businesswire.com with their article: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Envision Healthcare Corporation (EVHC) on Behalf …” published on June 11, 2018, Benzinga.com published: “Envision Healthcare To Go Private In $9.9B, All-Cash Deal” on June 11, 2018. More interesting news about Envision Healthcare Corporation (NYSE:EVHC) were released by: Seekingalpha.com and their article: “Reuters: HCA, KKR teaming on Envision buyout bid; EVHC +7.8%” published on May 18, 2018 as well as Businesswire.com‘s news article titled: “INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Envision Healthcare …” with publication date: June 15, 2018.

Envision Healthcare Corporation (NYSE:EVHC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.